“Our long-term plan is to take the same management team and the same device, and the same formula for success, and apply them to much larger patent-protected market opportunities. Those being depression, obesity, and Alzheimer's,”
“Unfortunately for the large number of Americans and their families who are trying to live with TRD and their psychiatrists who are trying to help them, the Senate Finance Committee [Feb. 16] issued a report without having interviewed world-renowned experts on TRD, widely published biostatisticians, patients and families living with TRD, patient advocacy organizations like NAMI, VNS Therapy TRD study investigators, and all the FDA statisticians and clinicians involved in the review of the submissions, that ultimately led to the approval of the only FDA-approved treatment option for TRD.”
